ENDRA Life Sciences (NDRA) has received a notice from Nasdaq Listing Qualifications staff indicating that it has regained compliance with the minimum $2.5 million in stockholders' equity requirement, the company said Thursday.
The company will remain subject to a discretionary panel monitor for a period of one year, the company said in a regulatory filing.